|
The
company, which also raised its full-year adjusted earnings
forecast, said revenue from its global vaccines unit rose 44
percent to $1.58 billion. The unit accounted for about 13
percent of Pfizer's total revenue.
Ibrance, approved by the U.S. Food and Drug Administration in
February, generated $140 million in revenue in the second
quarter.
Pfizer's shares rose about 2 percent in premarket trading on
Tuesday.
The drugmaker raised its adjusted profit forecast for 2015 to
$2.01-$2.07 per share from $1.95-$2.05.
It increased the lower end of its revenue forecast to $45
billion from $44 billion, maintaining the upper end at $46
billion.
Pfizer, which got nearly two-thirds of its 2014 revenue from
markets outside the United States, had cut its full-year revenue
and profit forecast in April, citing a strong dollar.
The company's net income fell to $2.63 billion, or 42 cents per
share, in the second quarter from $2.91 billion, or 45 cents per
share, a year earlier.
Excluding items, Pfizer earned 56 cents per share.
Revenue fell 7 percent to $11.85 billion, hurt by a stronger
dollar.
Analysts on average had expected a profit of 52 cents per share
and revenue of $11.42 billion, according to the Thomson Reuters
I/B/E/S.
Pfizer's shares were trading at $34.93 before the bell. The
stock had risen 7 percent in the six months to June 30.
(Reporting by Ankur Banerjee in Bengaluru; Editing by Simon
Jennings and Kirti Pandey)
[© 2015 Thomson Reuters. All rights
reserved.] Copyright 2015 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
 |
|
